🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,263 results for “Cancer” Clear

  1. CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GEMSOL, 40 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI

    Bristol-Myers Squibb / Pfizer EEIG

    Bladder Cancer Muscle-Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  2. CMF regimen

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    2 trials

  3. CTX-009

    Compass Therapeutics

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  4. CYCLOPHOSPHAMIDE, EPIRUBICIN, TRASTUZUMAB EMTANSINE, PACLITAXEL, DOXORUBICIN, DOCETAXEL, PACLITAXEL ALBUMIN-BOUND, TRASTUZUMAB, CARBOPLATIN, Phesgo 1200 mg/600 mg solution for injection, Phesgo 600 mg/600 mg solution for injection, TRASTUZUMAB, PERTUZUMAB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    HER2-positive early breast cancer

    phase 3 small molecule active

    1 trial

  5. CYCLOPHOSPHAMIDE, Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion., DOXORUBICIN, DOCETAXEL

    Cancer Prevention Pharma (Ireland) Limited

    oestrogen-receptor (ER)-positive HER2-negative breast carcinoma

    phase 3 small molecule active

    1 trial

  6. CYCLOPHOSPHAMIDE, PACLITAXEL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, CAPECITABINE, EPIRUBICIN, IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE, CARBOPLATIN, INFLIXIMAB, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, PEMBROLIZUMAB, Datopotamab deruxtecan, Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, MYCOPHENOLATE MOFETIL, DOXORUBICIN

    AstraZeneca AB

    Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  7. Cabozantinib

    Takeda Pharmaceuticals International AG

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  8. Cabozantinib, SELPERCATINIB, VANDETANIB, SELPERCATINIB, Cabozantinib, CABOZANTINIB

    Eli Lilly Co.

    RET-Mutant Medullary Thyroid Cancer

    phase 3 small molecule active

    1 trial

  9. Camrelizumab

    First Tracks Biotherapeutics

    Esophageal Cancer

    phase 3 small molecule active

    2 trials

  10. Capecitabine Accord 150 mg film-coated tablets, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Irinotecan Accord 20 mg/ml Solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion

    Cancer Prevention Pharma (Ireland) Limited

    Stage III colorectal cancer

    phase 3 small molecule active

    1 trial

  11. Capecitabine monotherapy

    First Tracks Biotherapeutics

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  12. Capivasertib, Faslodex 250 mg solution for injection., Placebo to Capivasertib, Capivasertib

    AstraZeneca AB

    Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer

    phase 3 small molecule active

    1 trial

  13. Capivasertib, Placebo for capivasertib film-coated tablet for oral use, ABIRATERONE ACETATE, Capivasertib

    AstraZeneca AB

    Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency

    phase 3 small molecule active

    1 trial

  14. Capox chemotherapy

    China SXT Pharmaceuticals

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  15. Carboplatin

    Teva Pharma GmbH

    Tubular Breast Cancer Stage II

    phase 3 small molecule completed

    1 trial

  16. Carboplatin

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    1 trial

  17. Carboplatin

    Alaunos Therapeutics

    Extensive-Stage Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DS-8201a

    Daiichi Sankyo Europe GmbH

    HER2-expressing endometrial cancer (IHC 3+/2+)

    phase 3 small molecule active

    1 trial

  19. Casodex 50 mg Film-coated Tablets, Zoladex 10,8 mg implantat

    Pharma Mar S.A.

    Metastatic hormone-sensitive prostate cancer with high tumor load

    phase 3 small molecule active

    1 trial

  20. Casodex® 50 mg Film-coated Tablets, ANANDRON 150 mg, comprimé, Flutamide 250 mg Tablets, Xtandi - 40 mg soft capsules

    Cancer Prevention Pharma (Ireland) Limited

    Localised prostate cancer at high risk of recurrence

    phase 3 small molecule active

    1 trial

  21. Celecoxib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  22. Chemotherapy

    First Tracks Biotherapeutics

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  23. Chirhostim

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Pancreatic cancer, Intraductal papillary mucinous intraductal neoplasia

    phase 3 small molecule active

    1 trial

  24. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Cancer Prevention Pharma (Ireland) Limited

    Advanced head and neck cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources